Your browser doesn't support javascript.
loading
Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States.
Kalirai, Samaneh; Ivanova, Jasmina I; Perez-Nieves, Magaly; Stephenson, Judith J; Hadjiyianni, Irene; Grabner, Michael; Pollom, Roy Daniel; Geremakis, Caroline; Reed, Beverly L; Fisher, Lawrence.
Afiliación
  • Kalirai S; Eli Lilly and Company, Indianapolis, IN, USA.
  • Ivanova JI; Analysis Group Inc., New York, NY, USA.
  • Perez-Nieves M; Eli Lilly and Company, Indianapolis, IN, USA.
  • Stephenson JJ; HealthCore Inc., Wilmington, DE, USA.
  • Hadjiyianni I; Eli Lilly and Company, Indianapolis, IN, USA.
  • Grabner M; HealthCore Inc., Wilmington, DE, USA.
  • Pollom RD; Eli Lilly and Company, Indianapolis, IN, USA.
  • Geremakis C; HealthCore Inc., Wilmington, DE, USA.
  • Reed BL; Eli Lilly and Company, Indianapolis, IN, USA.
  • Fisher L; Department of Family and Community Medicine, UC San Francisco, San Francisco, CA, USA.
Diabetes Metab Syndr Obes ; 13: 1023-1033, 2020.
Article en En | MEDLINE | ID: mdl-32308452
ABSTRACT

OBJECTIVE:

A survey of US adults with type 2 diabetes mellitus was conducted to better understand patients' insulin initiation experiences and treatment persistence behaviors. RESEARCH DESIGN AND

METHODS:

Participants were recruited from consumer panels and grouped by basal insulin treatment pattern continuers (no gap of ≥7 days within 6 months of initiation); interrupters (gap ≥7 days, resumed treatment); discontinuers (stopped for ≥7 days, not resumed). A quota of approximately 50 respondents per persistence category was set.

RESULTS:

A total of 154 respondents (52 continuers, 52 interrupters, 50 discontinuers) completed the survey. Mean age was 51.4 years; 51.9% male. Continuers were more likely to report their views being considered during initiation, and less likely to report a sense of failure. Concerns included insulin dependence (64.3% agree/strongly agree), frequent blood glucose monitoring (55.2%), costs/ability to pay (53.9%), fears of or mistakes during self-injection (52.6%), and weight gain (52.6%). Continuers were motivated by benefits of insulin therapy; experienced or potential side effects were notable factors for interruption/discontinuation. Healthcare provider instruction was indicated as a reason for continuing, stopping, and restarting therapy.

CONCLUSION:

Benefits of basal insulin therapy motivated continuers while side effects impacted interruption/discontinuation. Persistence on basal insulin is often influenced by provider actions. Earlier provider intervention upon signs of treatment discontinuation may promote persistence.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Diabetes Metab Syndr Obes Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Diabetes Metab Syndr Obes Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
...